Prof. Dr. Hsuan Liu | Cancer Biology | Excellence in Research Award
Chang Gung University | Taiwan
Hsuan Liu is a dedicated molecular medicine scholar whose career reflects sustained commitment to advancing biochemical and genomic research. He built his academic foundation through comprehensive training in biology, basic medical sciences, and molecular medicine at leading institutions in Taiwan, which prepared him for an intensive research trajectory in biomedical sciences. His professional journey includes progressive roles in major academic and research centers, where he contributed to molecular biology, pharmacology, and biomedical sciences before joining Chang Gung University as a faculty member, eventually advancing to the role of associate professor. His research interests span molecular oncology, RNA editing, non-coding RNA regulation, cancer genomics, immunogenomics, and the molecular mechanisms underlying tumor progression and therapeutic responses. He is skilled in high-throughput sequencing analysis, functional genomics, transcriptomic profiling, molecular cloning, RNA biology, bioinformatics, and translational cancer research, often integrating computational and experimental approaches. His achievements have been recognized through prestigious postdoctoral fellowships and awards highlighting his scientific excellence and contributions to cellular and molecular biology. Throughout his career, he has mentored graduate students and contributed to impactful publications that enhance understanding of cancer biology. Overall, Hsuan Liu stands as a committed researcher whose work continues to support scientific innovation and improved biomedical knowledge.
Profile: Scopus
Featured Publications
Huang, S.-C., Chang, I. Y.-F., Chang, C.-J., Liu, H., Chen, K.-H., Liu, T.-T., Hsieh, T.-Y., Chuang, H.-C., Chen, C.-C., Lin, I.-C., Ng, K.-F., Huang, H.-Y., & Chen, T.-C. (2023, February). Association between hepatic angiosarcoma and end-stage renal disease: Nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. The Journal of Pathology. Advance online publication.
Hsieh, C.-H., Kuan, W.-H., Chang, W.-L., Kuo, I.-Y., Hsun, L., Shieh, D.-B., Liu, H., Tan, B., & Wang, Y.-C. (2022, October). Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. Journal of Biomedical Science, 29(1), 90.
Yang, C.-K., Hsu, H.-C., Liu, Y.-H., Tsai, W.-S., Ma, C.-P., Chen, Y.-T., Tan, B.-C.-M., Lai, Y.-Y., Chang, I. Y.-F., Yang, C., Yang, C.-Y., Yu, J.-S., & Liu, H. (2022, July). EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response. Cell Oncology (Dordrecht), 45(4), 621–638.
Chen, Y.-T., Kan, C.-H., Liu, H., Liu, Y.-H., Wu, C.-C., Kuo, Y.-P., Chang, I. Y.-F., Chang, K.-P., Yu, J.-S., & Tan, B.-C.-M. (2022, July). Modular scaffolding by lncRNA HOXA10-AS promotes oral cancer progression. Cell Death & Disease, 13(7), 629.